Breaking News Instant updates and real-time market news.

ILMN

Illumina

$184.85

0.36 (0.20%)

, TMO

Thermo Fisher

$159.11

0.9 (0.57%)

16:17
10/10/16
10/10
16:17
10/10/16
16:17

Illumina to resume trading at 4:35 pm ET

Illumina (ILMN) shares, which were halted before the company lowered its quarterly revenue forecast, driven by a larger than anticipated year-over-year decline in high throughput sequencing instruments, are scheduled to resume trading at 4:35 pm ET. Quotation is scheduled to resume at 4:30 pm ET, according to Nasdaq. Shares of Thermo Fisher (TMO) are down 1% following Illumina's revenue cut, while QIAGEN (QGEN) shares are fractionally lower and Pacific Biosciences (PACB) has fallen 6%.

ILMN

Illumina

$184.85

0.36 (0.20%)

TMO

Thermo Fisher

$159.11

0.9 (0.57%)

PACB

Pacific Biosciences

$9.05

0.18 (2.03%)

QGEN

QIAGEN

$27.57

0.19 (0.69%)

  • 27

    Oct

ILMN Illumina
$184.85

0.36 (0.20%)

08/18/16
WELS
08/18/16
NO CHANGE
WELS
Wells Fargo says Thermo Fisher buying Illumina 'makes no sense'
Wells Fargo analyst Tim Evans believes speculation of Thermo Fisher (TMO) acquiring Illumina "makes no sense." The analyst estimates the deal would be about 14% dilutive to Thermo in year one and "would struggle to be neutral" to earnings by year three. Further, the deal would run into "significant regulatory hurdles" since that Illumina holds a near monopoly in high-throughput sequencing, Evans tell investors note. Shares of Illumina are off their highs but remain up 3% after StreetInsider stoked renewed takeout speculation by citing a source saying Thermo may bid $30B for the company.
08/18/16
CANT
08/18/16
NO CHANGE
Target $165
CANT
Speculative Buy
Thermo Fisher unlikely to acquire Illumina, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes it is unlikely that Thermo Fisher (TMO) will attempt to acquire Illumina (ILMN). Even if Thermo were to attempt a deal, the merger would be unlikely to close, Brokmeier tells investors in an intraday research note. If Illumina is a willing seller, however, Roche (RHHBY) may reconsider a bid, the analyst contends. He recommends investors stay on the sidelines with respect to Illumina shares. Brokmeier has a Hold rating on the name with a $165 price target. The analyst continues to believe Roche is the most likely acquirer of Pacific Biosciences (PACB).
08/22/16
KING
08/22/16
DOWNGRADE
KING
Neutral
Illumina downgraded to Neutral from Buy at CL King
CL King analyst David Westenberg downgraded Illumina to Neutral given the recent run-up in the shares and lack of near-term visible catalysts.
09/12/16
SBSH
09/12/16
NO CHANGE
Target $190
SBSH
Buy
Illumina price target raised to $190 from $175 at Citi
Citi analyst Daniel Arias raised his price target for Illumina to $190 after traveling with the company's CFO Marc Stapley and investor relations head Rebecca Chambers. The analyst believes the business "can hold its own" in the second half of 2016 and that shares can move higher in 2017. He keeps a Buy rating on Illumina.
TMO Thermo Fisher
$159.11

0.9 (0.57%)

09/22/16
JPMS
09/22/16
INITIATION
Target $180
JPMS
Overweight
Thermo Fisher reinstated with Overweight, added to Focus List at JPMorgan
JPMorgan analyst Tycho Peterson reinstated Thermo Fisher Scientific with an Overweight rating and raised his price target for the shares to $180 from $160. The rating is unchanged from the firm's prior coverage. Peterson added Thermo to his firm's Analyst Focus List as a value pick.
09/09/16
CLVD
09/09/16
DOWNGRADE
CLVD
Neutral
Thermo Fisher downgraded to Neutral from Buy at Cleveland Research
Cleveland Research analyst Steve Willoughby downgraded Thermo Fisher to Neutral following checks that indicate softer trends. The firm's feedback points to concerns over the remainder of the year and the polity change in China that could impact year-end equipment sales in the country.
08/24/16
CLVD
08/24/16
NO CHANGE
CLVD
Thermo Fisher, VWR Q3 estimates trimmed at Cleveland Research
Cleveland Research analyst Steve Willoughby's research suggests the Life Science Industry has gotten off to a slow start in Q3 due to a modest deceleration among pharma customers, European softness following Brexit, and concerns over a slowdown in US government funding. The analyst trimmed estimates on Thermo Fisher (TMO) and VWR (VWR) pending further research.
PACB Pacific Biosciences
$9.05

0.18 (2.03%)

04/18/16
PIPR
04/18/16
NO CHANGE
Target $11
PIPR
Neutral
Pacific Biosciences estimates lowered on Sequel checks at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his Q1 estimates for Pacific Biosciences after his initial round of Sequel channel checks found six placements during the quarter compared to the 17 he modeled. Assuming Roche placed five systems, the Q1 total would come to 11, Quirk tells investors in a research note. The analyst keeps a Neutral rating on the shares with an $11 price target.
04/22/16
CANT
04/22/16
NO CHANGE
CANT
Pacific Biosciences should be bought after strong Q1 results, says Cantor
Cantor recommends that investors buy the shares of Pacific Biosciences after the company reported stronger than expected Q1 results. The firm thinks that the company's increased guidance may be conservative, and it believes that the company could have at least 30 bookings in Q2. Cantor keeps an $18 price target and Buy rating on the shares.
08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
QGEN QIAGEN
$27.57

0.19 (0.69%)

11/12/15
STFL
11/12/15
INITIATION
STFL
Hold
QIAGEN initiated with a Hold at Stifel
11/12/15
11/12/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accuray (ARAY) initiated with a Sell at Citi... Becton Dickinson (BDX) initiated with a Neutral at Citi... Boston Scientific (BSX) initiated with a Buy at Citi... Bruker (BRKR) initiated with a Buy at Stifel... C.R. Bard (BCR) initiated with a Buy at Citi... Cepheid (CPHD) initiated with a Buy at Stifel... CorMedix (CRMD) initiated with a Buy at Rodman & Renshaw... CoreSite Realty (COR) initiated with a Buy at BB&T... Digital Realty (DLR) initiated with a Buy at BB&T... DuPont Fabros (DFT) initiated with a Hold at BB&T... Duke Realty (DRE) initiated with a Hold at BB&T... Edwards Lifesciences (EW) initiated with a Sell at Citi... Electronic Arts (EA) initiated with an Outperform at Oppenheimer... EyeGate (EYEG) initiated with a Buy at Maxim... Glu Mobile (GLUU) initiated with a Perform at Oppenheimer... Integra LifeSciences (IART) initiated with a Buy at Citi... Intuitive Surgical (ISRG) initiated with a Buy at Citi... Mast Therapeutics (MSTX) initiated with a Buy at Maxim... Medgenics (MDGN) initiated with a Buy at Needham... Novocure (NVCR) initiated with a Buy at Evercore ISI... Prologis (PLD) initiated with a Hold at BB&T... QIAGEN (QGEN) initiated with a Hold at Stifel... Rocket Fuel (FUEL) initiated with a Neutral at Boenning & Scattergood... STAG Industrial (STAG) initiated with an Underweight at BB&T... Stryker (SYK) initiated with a Sell at Citi... Tremor Video (TRMR) initiated with an Outperform at Boenning & Scattergood... VOXX (VOXX) initiated with an Outperform at Oppenheimer... Varian Medical (VAR) initiated with a Neutral at Citi... Yahoo (YHOO) initiated with an Outperform at Boenning & Scattergood... YuMe (YUME) initiated with a Neutral at Boenning & Scattergood... Zimmer Biomet (ZBH) initiated with a Sell at Citi.
05/25/16
PIPR
05/25/16
NO CHANGE
PIPR
Neutral
Piper says QIAGEN may need to change or pull GeneReader if Illumina wins suit
Piper Jaffray analyst William Quirk said patent infringement outcomes are hard to predict, but added that Illumina's (ILMN) win at the Patent Trial and Appeal Board increase its chances to prevail in its recently filed infringement lawsuit against Qiagen (QGEN) related to the GeneReader DNA sequencer. If Illumina does win, Qiagen will need to "drastically" alter the product and/or remove it from the market, said Quirk, who keeps a Neutral rating on Qiagen shares.
08/01/16
HSBC
08/01/16
UPGRADE
HSBC
Buy
QIAGEN upgraded to Buy from Hold at HSBC
HSBC analyst Keppeler upgraded QIAGEN to Buy and increased its price target to $27 from $20. The analyst is more constructive on improving trends in Academia/Pharma and expects topline growth to accelerate to 7% in 2017 from 1-4% in 2012-2015 from strong growth drivers that include QiaSymphony instrument and the NGS franchise.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.